{
    "response": "**Overall Treatment Decision:** Yes\u2014treat\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute disabling relapse with cerebellar ataxia and optic neuritis features Improves speed of neurological recovery Low risk once infection is excluded\n\n*   **Treatment:** Proton pump inhibitor for gastric protection\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** High-dose corticosteroid therapy increases GI risk Prevention of steroid-induced dyspepsia/ulceration\n\n*   **Treatment:** Physiotherapy and gait/fall-prevention programme\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Ataxic, unsteady gait Reduces fall risk and promotes functional recovery\n\n*   **Treatment:** Low-molecular-weight heparin for VTE prophylaxis (unless contraindicated)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility due to cerebellar ataxia and limb weakness Prevents deep vein thrombosis\n\n*   **Treatment:** Oral baclofen for spasticity\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Right lower-limb spasticity and clonus causing functional impairment Improves comfort and mobility\n\n*   **Treatment:** Plasma exchange\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for steroid-refractory acute relapse Greatest benefit within 2 weeks if inadequate response to steroids\n\n*   **Treatment:** High-efficacy disease-modifying therapy for MS (e.g., ocrelizumab or natalizumab, per eligibility)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate after confirmation of MS by MRI/CSF per McDonald criteria Requires infection screening, vaccination review, and risk stratification (e.g., JCV)\n\n*   **Treatment:** Vitamin D supplementation\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Safe and commonly deficient; deficiency is associated with MS activity Bone protection during and after corticosteroid use\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute disabling relapse with cerebellar ataxia and optic neuritis features\", \"Improves speed of neurological recovery\", \"Low risk once infection is excluded\"]}, {\"treatment\": \"Proton pump inhibitor for gastric protection\", \"timing\": \"Start Now\", \"reasons\": [\"High-dose corticosteroid therapy increases GI risk\", \"Prevention of steroid-induced dyspepsia/ulceration\"]}, {\"treatment\": \"Physiotherapy and gait/fall-prevention programme\", \"timing\": \"Start Now\", \"reasons\": [\"Ataxic, unsteady gait\", \"Reduces fall risk and promotes functional recovery\"]}, {\"treatment\": \"Low-molecular-weight heparin for VTE prophylaxis (unless contraindicated)\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility due to cerebellar ataxia and limb weakness\", \"Prevents deep vein thrombosis\"]}, {\"treatment\": \"Oral baclofen for spasticity\", \"timing\": \"Start Now\", \"reasons\": [\"Right lower-limb spasticity and clonus causing functional impairment\", \"Improves comfort and mobility\"]}, {\"treatment\": \"Plasma exchange\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for steroid-refractory acute relapse\", \"Greatest benefit within 2 weeks if inadequate response to steroids\"]}, {\"treatment\": \"High-efficacy disease-modifying therapy for MS (e.g., ocrelizumab or natalizumab, per eligibility)\", \"timing\": \"Delay\", \"reasons\": [\"Initiate after confirmation of MS by MRI/CSF per McDonald criteria\", \"Requires infection screening, vaccination review, and risk stratification (e.g., JCV)\"]}, {\"treatment\": \"Vitamin D supplementation\", \"timing\": \"Start Now\", \"reasons\": [\"Safe and commonly deficient; deficiency is associated with MS activity\", \"Bone protection during and after corticosteroid use\"]}]"
}